Company Description
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage.
It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers.
Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Country | United States |
Founded | 2018 |
IPO Date | May 27, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 181 |
CEO | Jeremy Bender |
Contact Details
Address: 1800 Sierra Point Parkway, Suite 200 Brisbane, California 94005 United States | |
Phone | 650 484 0899 |
Website | dayonebio.com |
Stock Details
Ticker Symbol | DAWN |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001845337 |
CUSIP Number | 23954D109 |
ISIN Number | US23954D1090 |
Employer ID | 83-2415215 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Jeremy Bender M.B.A., Ph.D. | Chief Executive Officer, President and Director |
Charles N. York II, M.B.A. | Chief Operating Officer, Chief Financial Officer and Secretary |
Adam Dubow J.D. | General Counsel and Chief Compliance Officer |
John Stubenrauch Ph.D. | Chief Technology Officer |
Jaa Roberson | Chief People Officer |
Dr. Davy Chiodin Ph.D., Pharm.D. | Chief Development Officer |
Lauren Merendino M.B.A. | Chief Commercial Officer |
Dr. Elly Barry M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 6, 2025 | 10-K/A | [Amend] Annual report |
Feb 25, 2025 | 10-K | Annual Report |
Feb 25, 2025 | 8-K | Current Report |
Feb 18, 2025 | 144 | Filing |
Feb 18, 2025 | 144 | Filing |
Feb 18, 2025 | 144 | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 12, 2025 | SCHEDULE 13G/A | Filing |
Jan 13, 2025 | 8-K | Current Report |
Jan 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |